Myeloid Growth Factors

Dale DC, McCarter GC, Crawford J. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw 2003;1:440–454.

• PubMed
DaleDCMcCarterGCCrawfordJ. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw 2003;1:440–454. )| false
• Search Google Scholar
• Export Citation

Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002;62(Suppl 1):1–15.

• PubMed
DaleDC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002;62(Suppl 1):1–15. )| false
• Search Google Scholar
• Export Citation

Lyman GH, Kuderer NM. Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs 2002;62(Suppl 1):65–78.

• PubMed
LymanGHKudererNM. Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs 2002;62(Suppl 1):65–78. )| false
• Search Google Scholar
• Export Citation

Gisselbrecht C, Haioun C, Lepage E et al.. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin’s lymphoma: factors influencing chemotherapy administration. Groupe d’Etude des Lymphomes de l’Adulte. Leuk Lymphoma 1997;25:289–300.

• PubMed
GisselbrechtCHaiounCLepageE. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin’s lymphoma: factors influencing chemotherapy administration. Groupe d’Etude des Lymphomes de l’Adulte. Leuk Lymphoma 1997;25:289–300. )| false
• Search Google Scholar
• Export Citation

Timmer-Bonte JN, de Boo TM, Smit HJ et al.. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol 2005;23:7974–7984.

• PubMed
Timmer-BonteJNde BooTMSmitHJ. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol 2005;23:7974–7984. )| false
• Search Google Scholar
• Export Citation

Trillet-Lenoir V, Green J, Manegold C et al.. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319–324.

• PubMed
Trillet-LenoirVGreenJManegoldC. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319–324. )| false
• Search Google Scholar
• Export Citation

Vogel CL, Wojtukiewicz MZ, Carroll RR et al.. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178–1184.

• PubMed
VogelCLWojtukiewiczMZCarrollRR. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178–1184. )| false
• Search Google Scholar
• Export Citation

Bui BN, Chevallier B, Chevreau C et al.. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol 1995;13:2629–2636.

• PubMed
BuiBNChevallierBChevreauC. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol 1995;13:2629–2636. )| false
• Search Google Scholar
• Export Citation

Chevallier B, Chollet P, Merrouche Y et al.. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995;13:1564–1571.

• PubMed
ChevallierBCholletPMerroucheY. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995;13:1564–1571. )| false
• Search Google Scholar
• Export Citation

Crawford J, Ozer H, Stoller R et al.. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164–170.

• PubMed
CrawfordJOzerHStollerR. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164–170. )| false
• Search Google Scholar
• Export Citation

Gatzemeier U, Kleisbauer JP, Drings P et al.. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol 2000;23:393–400.

• PubMed
GatzemeierUKleisbauerJPDringsP. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol 2000;23:393–400. )| false
• Search Google Scholar
• Export Citation

Muhonen T, Jantunen I, Pertovaara H et al.. Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. Am J Clin Oncol 1996;19:232–234.

• PubMed
MuhonenTJantunenIPertovaaraH. Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. Am J Clin Oncol 1996;19:232–234. )| false
• Search Google Scholar
• Export Citation

Osby E, Hagberg H, Kvaloy S et al.. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003;101:3840–3848.

• PubMed
OsbyEHagbergHKvaloyS. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003;101:3840–3848. )| false
• Search Google Scholar
• Export Citation

Pettengell R, Gurney H, Radford JA et al.. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood 1992;80:1430–1436.

• PubMed
PettengellRGurneyHRadfordJA. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood 1992;80:1430–1436. )| false
• Search Google Scholar
• Export Citation

Zinzani PL, Pavone E, Storti S et al.. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin’s lymphoma. Blood 1997;89:3974–3979.

• PubMed
ZinzaniPLPavoneEStortiS. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin’s lymphoma. Blood 1997;89:3974–3979. )| false
• Search Google Scholar
• Export Citation

Doorduijn JK, van der Holt B, van Imhoff GW et al.. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2003;21:3041–3050.

• PubMed
DoorduijnJKvan der HoltBvan ImhoffGW. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2003;21:3041–3050. )| false
• Search Google Scholar
• Export Citation

Fossa SD, Kaye SB, Mead GM et al.. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998;16:716–724.

• PubMed
FossaSDKayeSBMeadGM. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998;16:716–724. )| false
• Search Google Scholar
• Export Citation

Citron ML, Berry DA, Cirrincione C et al.. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431–1439.

• PubMed
CitronMLBerryDACirrincioneC. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431–1439. )| false
• Search Google Scholar
• Export Citation

Pfreundschuh M, Trumper L, Kloess M et al.. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634–641.

• PubMed
PfreundschuhMTrumperLKloessM. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634–641. )| false
• Search Google Scholar
• Export Citation

Bohlius J, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2004:CD003189.

• PubMed
BohliusJReiserMSchwarzerGEngertA. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2004:CD003189. )| false
• Search Google Scholar
• Export Citation

Sung L, Nathan PC, Alibhai SM et al.. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007;147:400–411.

• PubMed
SungLNathanPCAlibhaiSM. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007;147:400–411. )| false
• Search Google Scholar
• Export Citation

Clark OA, Lyman GH, Castro AA et al.. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005;23:4198–4214.

• PubMed
ClarkOALymanGHCastroAA. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005;23:4198–4214. )| false
• Search Google Scholar
• Export Citation

Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158–3167.

• PubMed
KudererNMDaleDCCrawfordJLymanGH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158–3167. )| false
• Search Google Scholar
• Export Citation

Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 2004;50:129–146.

• PubMed
LymanGHKudererNM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 2004;50:129–146. )| false
• Search Google Scholar
• Export Citation

Cosler LE, Eldar-Lissai A, Culakova E et al.. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. Pharmacoeconomics 2007;25:343–351.

• PubMed
CoslerLEEldar-LissaiACulakovaE. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. Pharmacoeconomics 2007;25:343–351. )| false
• Search Google Scholar
• Export Citation

Doorduijn JK, Buijt I, van der Holt B et al.. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin’s lymphoma. Haematologica 2004;89:1109–1117.

• PubMed
DoorduijnJKBuijtIvan der HoltB. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin’s lymphoma. Haematologica 2004;89:1109–1117. )| false
• Search Google Scholar
• Export Citation

Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 2008;11:172–179.

• PubMed
Eldar-LissaiACoslerLECulakovaELymanGH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 2008;11:172–179. )| false
• Search Google Scholar
• Export Citation

Numnum TM, Kimball KJ, Rocconi RP et al.. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma—a cost-effectiveness analysis. Int J Gynecol Cancer 2007;17:1019–1024.

• PubMed
NumnumTMKimballKJRocconiRP. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma—a cost-effectiveness analysis. Int J Gynecol Cancer 2007;17:1019–1024. )| false
• Search Google Scholar
• Export Citation

Timmer-Bonte JN, Adang EM, Termeer E et al.. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. J Clin Oncol 2008;26:290–296.

• PubMed
Timmer-BonteJNAdangEMTermeerE. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. J Clin Oncol 2008;26:290–296. )| false
• Search Google Scholar
• Export Citation

U.S. Food and Drug Administration. FDA filgrastim and pegfilgrastim labels. Available at: http://www.fda.gov/cder/foi/label/2006/103353s5086LBL.pdf and http://www.fda.gov/cder/foi/label/2007/125031s082lbl.pdf. Accessed October 29, 2008.

• PubMed
U.S. Food and Drug Administration. FDA filgrastim and pegfilgrastim labels. Available at: http://www.fda.gov/cder/foi/label/2006/103353s5086LBL.pdf and http://www.fda.gov/cder/foi/label/2007/125031s082lbl.pdf. Accessed October 29, 2008. )| false
• Search Google Scholar
• Export Citation

Martin WG, Ristow KM, Habermann TM et al.. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 2005;23:7614–7620.

• PubMed
MartinWGRistowKMHabermannTM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 2005;23:7614–7620. )| false
• Search Google Scholar
• Export Citation

Tigue CC, McKoy JM, Evens AM et al.. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007;40:185–192.

• PubMed
TigueCCMcKoyJMEvensAM. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007;40:185–192. )| false
• Search Google Scholar
• Export Citation

Aapro MS, Cameron DA, Pettengell R et al.. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433–2453.

• PubMed
AaproMSCameronDAPettengellR. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433–2453. )| false
• Search Google Scholar
• Export Citation

Smith TJ, Khatcheressian J, Lyman GH et al.. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187–3205.

• PubMed
SmithTJKhatcheressianJLymanGH. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187–3205. )| false
• Search Google Scholar
• Export Citation

Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228–237.

• PubMed
CrawfordJDaleDCLymanGH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228–237. )| false
• Search Google Scholar
• Export Citation

Lyman GH. Risk assessment in oncology clinical practice. From risk factors to risk models. Oncology (Williston Park) 2003;17:8–13.

• PubMed
LymanGH. Risk assessment in oncology clinical practice. From risk factors to risk models. Oncology (Williston Park) 2003;17:8–13. )| false
• Search Google Scholar
• Export Citation

Azoulay E, Attalah H, Harf A et al.. Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Systematic review of clinical case reports and experimental data. Chest 2001;120:1695–1701.

• PubMed
AzoulayEAttalahHHarfA. Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Systematic review of clinical case reports and experimental data. Chest 2001;120:1695–1701. )| false
• Search Google Scholar
• Export Citation

Evens AM, Cilley J, Ortiz T et al.. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007;137:545–552.

• PubMed
EvensAMCilleyJOrtizT. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007;137:545–552. )| false
• Search Google Scholar
• Export Citation

Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005;10:427–437.

• PubMed
LymanGHLymanCHAgboolaO. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005;10:427–437. )| false
• Search Google Scholar
• Export Citation

Aslani A, Smith RC, Allen BJ et al.. The predictive value of body protein for chemotherapy-induced toxicity. Cancer 2000;88:796–803.

• PubMed
AslaniASmithRCAllenBJ. The predictive value of body protein for chemotherapy-induced toxicity. Cancer 2000;88:796–803. )| false
• Search Google Scholar
• Export Citation

Chrischilles E, Delgado DJ, Stolshek BS et al.. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin’s lymphoma. Cancer Control 2002;9:203–211.

• PubMed
ChrischillesEDelgadoDJStolshekBS. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin’s lymphoma. Cancer Control 2002;9:203–211. )| false
• Search Google Scholar
• Export Citation

Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003;98:2402–2409.

• PubMed
LymanGHDelgadoDJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003;98:2402–2409. )| false
• Search Google Scholar
• Export Citation

Lyman GH, Morrison VA, Dale DC et al.. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003;44:2069–2076.

• PubMed
LymanGHMorrisonVADaleDC. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003;44:2069–2076. )| false
• Search Google Scholar
• Export Citation

Morrison VA, Picozzi V, Scott S et al.. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin’s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2001;2:47–56.

• PubMed
MorrisonVAPicozziVScottS. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin’s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2001;2:47–56. )| false
• Search Google Scholar
• Export Citation

Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21: 4524–4531.

• PubMed
LymanGHDaleDCCrawfordJ. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21: 4524–4531. )| false
• Search Google Scholar
• Export Citation

Lyman GH, Dale DC, Friedberg J et al.. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 2004;22:4302–4311.

• PubMed
LymanGHDaleDCFriedbergJ. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol 2004;22:4302–4311. )| false
• Search Google Scholar
• Export Citation

Berghmans T, Paesmans M, Lafitte JJ et al.. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 2002;10:181–188.

• PubMed
BerghmansTPaesmansMLafitteJJ. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 2002;10:181–188. )| false
• Search Google Scholar
• Export Citation

Garcia-Carbonero R, Mayordomo JI, Tornamira MV et al.. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001;93:31–38.

• PubMed
Garcia-CarboneroRMayordomoJITornamiraMV. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001;93:31–38. )| false
• Search Google Scholar
• Export Citation

Johnston E, Crawford J, Blackwell S et al.. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522–2528.

• PubMed
JohnstonECrawfordJBlackwellS. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522–2528. )| false
• Search Google Scholar
• Export Citation

Crawford J. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol 2003;30:24–30.

• PubMed
CrawfordJ. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol 2003;30:24–30. )| false
• Search Google Scholar
• Export Citation

Lokich JJ. Same day pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma. Am J Clin Oncol 2006;29:361–363.

• PubMed
LokichJJ. Same day pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma. Am J Clin Oncol 2006;29:361–363. )| false
• Search Google Scholar
• Export Citation

Kaufman PA, Paroly W, Rinaldi D. Randomized double blind phase 2 study evaluating same-day vs. next-day administration of pegfilgrastim with docetaxel, doxorubicin and cyclophosphamide (TAC) in women with early stage and advanced breast cancer SABCS [abstract]. Breast Cancer Res Treat 2004;88:Abstract 1054.

• PubMed
KaufmanPAParolyWRinaldiD. Randomized double blind phase 2 study evaluating same-day vs. next-day administration of pegfilgrastim with docetaxel, doxorubicin and cyclophosphamide (TAC) in women with early stage and advanced breast cancer SABCS [abstract]. Breast Cancer Res Treat 2004;88:Abstract 1054. )| false
• Search Google Scholar
• Export Citation

Belani CP, Ramalingam S, Al-Janadi A et al.. A randomized double-blind phase II study to evaluate same-day vs next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with NSCLC [abstract]. J Clin Oncol 2006;24(Suppl 1):Abstract 7110.

• PubMed
BelaniCPRamalingamSAl-JanadiA. A randomized double-blind phase II study to evaluate same-day vs next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with NSCLC [abstract]. J Clin Oncol 2006;24(Suppl 1):Abstract 7110. )| false
• Search Google Scholar
• Export Citation

Stull DM, Bilmes R, Kim H, Fichtl R. Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia. Am J Health Syst Pharm 2005;62:83–87.

• PubMed
StullDMBilmesRKimHFichtlR. Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia. Am J Health Syst Pharm 2005;62:83–87. )| false
• Search Google Scholar
• Export Citation

Dale DC, Bonilla MA, Davis MW et al.. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993;81:2496–2502.

• PubMed
DaleDCBonillaMADavisMW. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993;81:2496–2502. )| false
• Search Google Scholar
• Export Citation